Objective: High levels of soluble CD40 ligand (sCD40L) in the circulation have been suggested as an important indicator of cardiovascular diseases such as atherosclerosis and acute coronary syndromes. In the present study, we explored the role of sCD40L in the formation of foam cells. Methods: Lipid deposition and foam cell formation was measured by high-performance liquid chromatography and Nile Red staining, respectively. Gene expressions were detected by quantitative real-time PCR and Western blot analysis. The interaction between CD40 and sCD40L were blocked by CD40 small interfering RNA or anti-CD40 antibody. Results: sCD40L significantly increased lipid deposition and foam cell formation associated with upregulation of scavenger receptor type A and CD36. Additionally, sCD40L increased adipocyte enhancer-binding protein 1 and cholesterol efflux, and activated NF-κB in macrophages. sCD40L promoted foam cell formation via CD40 ligation and disruption of the ligation between CD40 and CD40L either by small interfering RNA or by a blocking anti-CD40 antibody apparently inhibiting foam cell formation in response to sCD40L. Conclusion: Our data suggests a novel insight into the role of sCD40L in foam cell formation during atherosclerosis, which further confirms the importance of sCD40L in atherosclerosis and as a target for the treatment of this disease.

Keywords:
Atherosclerosis, Lipid deposition, Oxidized low-density lipoprotein, Scavenger receptor
1.
Cipollone F, Chiarelli F, Davi G, Ferri C, Desideri G, Fazia M, Iezzi A, Santilli F, Pini B, Cuccurullo C, Tumini S, Del Ponte A, Santucci A, Cuccurullo F, Mezzetti A: Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005;48:1216-1224.
2.
Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG: Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001;104:2395-2400.
3.
Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111.
4.
Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F: Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005;111:412-419.
5.
Kroczek RA, Graf D, Brugnoni D, Giliani S, Korthuer U, Ugazio A, Senger G, Mages HW, Villa A, Notarangelo LD: Defective expression of CD40 ligand on T cells causes ‘X-linked immunodeficiency with hyper-IgM (HIGM1)'. Immunol Rev 1994;138:39-59.
6.
Hassan GS, Merhi Y, Mourad W: CD40 ligand: a neo-inflammatory molecule in vascular diseases. Immunobiology 2012;217:521-532.
7.
Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ Res 2001;89:1092-1103.
8.
Ludewig B, Henn V, Schroder JM, Graf D, Kroczek RA: Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol 1996;26:3137-3143.
9.
Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR: Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896-899.
10.
Aukrust P, Waehre T, Damas JK, Gullestad L, Solum NO: Inflammatory role of platelets in acute coronary syndromes. Heart 2001;86:605-606.
11.
Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD: Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003;90:377-384.
12.
Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
13.
Lutgens E, Daemen MJ: CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002;12:27-32.
14.
Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-203.
15.
Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA: Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-1316.
16.
Chakrabarti S, Rizvi M, Pathak D, Kirber MT, Freedman JE: Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. Immunol Lett 2009;122:170-184.
17.
Jeon HJ, Choi JH, Jung IH, Park JG, Lee MR, Lee MN, Kim B, Yoo JY, Jeong SJ, Kim DY, Park JE, Park HY, Kwack K, Choi BK, Kwon BS, Oh GT: CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010;121:1124-1133.
18.
Nomura S, Shouzu A, Omoto S, Inami N, Shimazu T, Satoh D, Kajiura T, Yamada K, Urase F, Maeda Y, Iwasaka T: Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. Blood Coagul Fibrinolysis 2009;20:440-447.
19.
Oviedo-Orta E, Bermudez-Fajardo A, Karanam S, Benbow U, Newby AC: Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008;124:42-50.
20.
Libby P: Inflammation in atherosclerosis. Nature 2002;420:868-874.
21.
Watanabe T, Hirata M, Yoshikawa Y, Nagafuchi Y, Toyoshima H: Role of macrophages in atherosclerosis. Sequential observations of cholesterol-induced rabbit aortic lesion by the immunoperoxidase technique using monoclonal antimacrophage antibody. Lab Invest 1985;53:80-90.
22.
Ito T, Yamada S, Shiomi M: Progression of coronary atherosclerosis relates to the onset of myocardial infarction in an animal model of spontaneous myocardial infarction (WHHLMI rabbits). Exp Anim 2004;53:339-346.
23.
Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y: Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008;118:75-83.
24.
Ghosh S, Zhao B, Bie J, Song J: Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul Pharmacol 2010;52:1-10.
25.
Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL: CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007;75:468-477.
26.
Cheng LC, Su KH, Kou YR, Shyue SK, Ching LC, Yu YB, Wu YL, Pan CC, Lee TS: α-Lipoic acid ameliorates foam cell formation via liver X receptor α-dependent upregulation of ATP-binding cassette transporters A1 and G1. Free Radic Biol Med 2011;50:47-54.
27.
Häkkinen T, Karkola K, Ylä-Herttuala S: Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 2000;437:396-405.
28.
Seppen J, Rijnberg M, Cooreman MP, Oude Elferink RP: Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol 2002;36:459-465.
29.
Feng X, Zhang Y, Xu R, Xie X, Tao L, Gao H, Gao Y, He Z, Wang H: Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis 2010;208:396-405.
30.
Rios FJ, Jancar S, Melo IB, Ketelhuth DF, Gidlund M: Role of PPAR-gamma in the modulation of CD36 and FcgammaRII induced by LDL with low and high degrees of oxidation during the differentiation of the monocytic THP-1 cell line. Cell Physiol Biochem 2008;22:549-556.
31.
Wang J, Si Y, Wu C, Sun L, Ma Y, Ge A, Li B: Lipopolysaccharide promotes lipid accumulation in human adventitial fibroblasts via TLR4-NF-κB pathway. Lipids Health Dis 2012;11:139.
32.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
33.
Majdalawieh A, Zhang L, Fuki IV, Rader DJ, Ro HS: Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation. Proc Natl Acad Sci U S A 2006;103:2346-2351.
34.
Ferreira V, van Dijk KW, Groen AK, Vos RM, van der Kaa J, Gijbels MJ, Havekes LM, Pannekoek H: Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis 2007;192:283-290.
35.
Hachem A, Yacoub D, Zaid Y, Mourad W, Merhi Y: Involvement of nuclear factor κB in platelet CD40 signaling. Biochem Biophys Res Commun 2012;425:58-63.
36.
Chai H, Yan S, Wang H, Zhang R, Lin PH, Yao Q, Chen C: CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells. Surgery 2006;140:236-242.
37.
Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E: The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009;102:206-214.
38.
Lusis AJ: Atherosclerosis. Nature 2000;407:233-241.
39.
Davies MJ, Thomas AC: Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-373.
40.
Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995;92:657-671.
41.
Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW: Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-49988.
42.
Tsai JY, Su KH, Shyue SK, Kou YR, Yu YB, Hsiao SH, Chiang AN, Wu YL, Ching LC, Lee TS: EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res 2010;88:415-423.
43.
Pacenti M, Barzon L, Favaretto F, Fincati K, Romano S, Milan G, Vettor R, Palu G: Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS 2006;20:1691-1705.
44.
Zhang L, Reidy SP, Nicholson TE, Lee HJ, Majdalawieh A, Webber C, Stewart BR, Dolphin P, Ro HS: The role of AEBP1 in sex-specific diet-induced obesity. Mol Med 2005;11:39-47.
45.
Kim SW, Muise AM, Lyons PJ, Ro HS: Regulation of adipogenesis by a transcriptional repressor that modulates MAPK activation. J Biol Chem 2001;276:10199-10206.
46.
Majdalawieh A, Ro HS: LPS-induced suppression of macrophage cholesterol efflux is mediated by adipocyte enhancer-binding protein 1. Int J Biochem Cell Biol 2009;41:1518-1525.
47.
Bogachev O, Majdalawieh A, Pan X, Zhang L, Ro HS: Adipocyte enhancer-binding protein 1 (AEBP1) (a novel macrophage proinflammatory mediator) overexpression promotes and ablation attenuates atherosclerosis in ApoE (-/-) and LDLR (-/-) mice. Mol Med 2011;17:1056-1064.
48.
Huang Z, Dong F, Li S, Chu M, Zhou H, Lu Z, Huang W: Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 2012;690:164-169.
49.
Lee TS, Pan CC, Peng CC, Kou YR, Chen CY, Ching LC, Tsai TH, Chen SF, Lyu PC, Shyue SK: Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages. J Cell Biochem 2010;111:104-110.
50.
Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, Kolios G, Kouroumalis EA: Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:1147-1152.
51.
Chen Y, Chen J, Xiong Y, Da Q, Xu Y, Jiang X, Tang H: Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun 2006;345:106-117.
52.
Mehlhop PD, van de Rijn M, Brewer JP, Kisselgof AB, Geha RS, Oettgen HC, Martin TR: CD40L, but not CD40, is required for allergen-induced bronchial hyperresponsiveness in mice. Am J Respir Cell Mol Biol 2000;23:646-651.
53.
Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, Patko Z, Aikawa M, Schonbeck U, Bode C, Libby P, Peter K: CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007;115:1571-1580.
54.
Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M: A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887-896.
55.
May AE, Seizer P, Gawaz M: Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008;28:s5-s10.
56.
Gawaz M, Langer H, May AE: Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
57.
Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL 3rd, Michelson AD: Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004;43:2319-2325.
58.
Osto E, Kouroedov A, Mocharla P, Akhmedov A, Besler C, Rohrer L, von Eckardstein A, Iliceto S, Volpe M, Luscher TF, Cosentino F: Inhibition of protein kinase Cbeta prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. Circulation 2008;118:2174-2182.
59.
Fu H, Tang YY, Ouyang XP, Tang SL, Su H, Li X, Huang LP, He M, Lv YC, He PP, Yao F, Tan YL, Xie W, Zhang M, Wu J, Li Y, Chen K, Liu D, Lan G, Zeng MY, Zheng XL, Tang CK: Interleukin-27 inhibits foam cell formation by promoting macrophage ABCA1 expression through JAK2/STAT3 pathway. Biochem Biophys Res Commun 2014;452:881-887.
60.
Kawashima RL, Medh JD: Down-regulation of lipoprotein lipase increases ABCA1-mediated cholesterol efflux in THP-1 macrophages. Biochem Biophys Res Commun 2014;450:1416-1421.
61.
Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.